The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.
Verfahren zur Reindarstellung von 2-Chlor-6-alkoxy-3-nitropyridinen
申请人:RÜTGERSWERKE AKTIENGESELLSCHAFT
公开号:EP0102652A1
公开(公告)日:1984-03-14
Ein einfache Reindarstellung von 2-Chlor-6-alkoxy-3-nitropyridinen ergibt sich durch Nitrierung von 2-Chlor-6-alkoxypyridinen, wobei das jeweilige 2-Chlor-6-alkoxypryidin zum vorgelegten Nitriergemisch dosiert wird und durch anschließende Behandlung des noch verunreinigten 2-Chlor-6-alkoxy-3-nitropyridins mit einer Lösung einer alkalisch wirkenden Verbindung in einem protischen Lösungsmittel.
The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.